Development and validation of a high-performance liquid chromatographic assay using solid-phase extraction for the novel antitumor agent pancratistatin in human plasma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/90768
Title:
Development and validation of a high-performance liquid chromatographic assay using solid-phase extraction for the novel antitumor agent pancratistatin in human plasma.
Authors:
Khan, Parveen; Abbas, Sayara; Petit, B; Caffrey, Robert; Megram, Victoria; McGown, Alan T
Abstract:
The stability of the experimental anti-tumour agent pancratistatin in human plasma has been investigated. A solid-phase extraction technique and an HPLC assay with external standards have been developed and validated. Extraction was performed using C18 cartridges and HPLC, analysis was performed on a 15 cm Hypersil BDS column using isocratic elution with 13% acetonitrile and aqueous solution of 1% (w/v) acetic acid. The lower limit of quantification for pancratistatin in 5% DMF-95% water was found to be 0.58 ng/ml (+/-10.58%) and 2.3 ng/ml (+/-9.2%) following extraction from human plasma. Mean recovery of 89.4% (+/-4.73%) was obtained over the concentration range 0.0023-9.45 microg/ml for a five day validation study. Pancratistatin was stable at room temperature in light or dark for at least 15 days, in the refrigerator at 4 degrees C for at least 16 days and in the freezer at -20 degrees C or -80 degrees C for at least 28 days. Under all conditions monitored, % recovery of pancratistatin from human plasma was greater than 95% and no evidence of degradation had occurred. There also was no loss of pancratistatin after three cycles of freezing and thawing.
Affiliation:
Paterson Institute for Cancer Research, Section of Drug Development and Imaging, Withington, Manchester, UK. pkhan@picr.man.ac.uk
Citation:
Development and validation of a high-performance liquid chromatographic assay using solid-phase extraction for the novel antitumor agent pancratistatin in human plasma. 1999, 726 (1-2):249-54 J. Chromatogr. B Biomed. Sci. Appl.
Journal:
Journal of Chromatography. B, Biomedical Sciences and Applications
Issue Date:
16-Apr-1999
URI:
http://hdl.handle.net/10541/90768
DOI:
10.1016/S0378-4347(99)00053-5
PubMed ID:
10348192
Type:
Article
Language:
en
ISSN:
1387-2273
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorKhan, Parveenen
dc.contributor.authorAbbas, Sayaraen
dc.contributor.authorPetit, Ben
dc.contributor.authorCaffrey, Roberten
dc.contributor.authorMegram, Victoriaen
dc.contributor.authorMcGown, Alan Ten
dc.date.accessioned2010-01-28T13:51:56Z-
dc.date.available2010-01-28T13:51:56Z-
dc.date.issued1999-04-16-
dc.identifier.citationDevelopment and validation of a high-performance liquid chromatographic assay using solid-phase extraction for the novel antitumor agent pancratistatin in human plasma. 1999, 726 (1-2):249-54 J. Chromatogr. B Biomed. Sci. Appl.en
dc.identifier.issn1387-2273-
dc.identifier.pmid10348192-
dc.identifier.doi10.1016/S0378-4347(99)00053-5-
dc.identifier.urihttp://hdl.handle.net/10541/90768-
dc.description.abstractThe stability of the experimental anti-tumour agent pancratistatin in human plasma has been investigated. A solid-phase extraction technique and an HPLC assay with external standards have been developed and validated. Extraction was performed using C18 cartridges and HPLC, analysis was performed on a 15 cm Hypersil BDS column using isocratic elution with 13% acetonitrile and aqueous solution of 1% (w/v) acetic acid. The lower limit of quantification for pancratistatin in 5% DMF-95% water was found to be 0.58 ng/ml (+/-10.58%) and 2.3 ng/ml (+/-9.2%) following extraction from human plasma. Mean recovery of 89.4% (+/-4.73%) was obtained over the concentration range 0.0023-9.45 microg/ml for a five day validation study. Pancratistatin was stable at room temperature in light or dark for at least 15 days, in the refrigerator at 4 degrees C for at least 16 days and in the freezer at -20 degrees C or -80 degrees C for at least 28 days. Under all conditions monitored, % recovery of pancratistatin from human plasma was greater than 95% and no evidence of degradation had occurred. There also was no loss of pancratistatin after three cycles of freezing and thawing.en
dc.language.isoenen
dc.subject.meshAmaryllidaceae Alkaloids-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshChromatography, High Pressure Liquid-
dc.subject.meshHumans-
dc.subject.meshIsoquinolines-
dc.subject.meshReproducibility of Results-
dc.subject.meshSpectrophotometry, Ultraviolet-
dc.titleDevelopment and validation of a high-performance liquid chromatographic assay using solid-phase extraction for the novel antitumor agent pancratistatin in human plasma.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Section of Drug Development and Imaging, Withington, Manchester, UK. pkhan@picr.man.ac.uken
dc.identifier.journalJournal of Chromatography. B, Biomedical Sciences and Applicationsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.